NOVOLIN R (human insulin) by Novo Nordisk. Approved for insulin [epc]. First approved in 1991.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
NOVOLIN R is a human insulin product manufactured by Novo Nordisk, approved in 1991 for the treatment of diabetes mellitus. It is a rapid-acting insulin administered via subcutaneous injection that works by facilitating glucose uptake into cells and promoting anabolic processes. NOVOLIN R is positioned as a foundational insulin therapy option, particularly for patients requiring short-acting insulin coverage or those on insulin regimens combining rapid and intermediate-acting formulations.
Insulin
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Defining the Human Insulin Resistance Molecular Network; SIGNATURE
A Trial to Investigate Post Prandial Blood Glucose Control With Fast-acting Human Insulin HinsBet® Compared to Insulin Lispro (Humalog®) and Regular Human Insulin (Huminsulin® Normal) After Ingestion of a Standardized Meal in Subjects With T1DM
A Double-blinded, Randomised, Three-period Crossover Euglycaemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Human Insulin, Human Insulin (Huminsulin® Normal) and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes
A Study of LY2605541 (Insulin Peglispro) and Human Insulin Concentrations in Fat Tissue
Investigating Efficacy and Safety of Biphasic Insulin Aspart 50 Twice Daily Versus Biphasic Human Insulin 50 Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus
Worked on NOVOLIN R at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moNOVOLIN R supports careers in brand management, specialty pharmacy operations, and field sales, though with declining opportunity as the product enters the LOE phase. Relevant skill sets include healthcare economics, formulary management, reimbursement strategy, and managed care negotiations in the commoditized insulin market. Currently, zero job positions are actively linked to this product, reflecting limited growth and development activity at this mature lifecycle stage.